<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04209686</url>
  </required_header>
  <id_info>
    <org_study_id>J19135</org_study_id>
    <secondary_id>IRB00209006</secondary_id>
    <nct_id>NCT04209686</nct_id>
  </id_info>
  <brief_title>Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma</brief_title>
  <official_title>Phase 2 Study of Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and clinical activity of paclitaxel plus
      olaparib and pembrolizumab in patients with previously treated advanced Gastric Cancer (GC).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">July 2024</completion_date>
  <primary_completion_date type="Anticipated">July 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>4 years</time_frame>
    <description>OS will be measured from date of first dose until death or end of follow-up (OS will be censored on the date the subject was last known to be alive for subjects without documentation of death at the time of analysis). Estimation based on the Kaplan-Meier curve.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants experiencing a grade 3 or above study drug-related adverse event</measure>
    <time_frame>4 years</time_frame>
    <description>When calculating the incidence of adverse events (AEs), each AE (as defined by NCI CTCAE v5.0) will be counted only once for a given subject. Estimation based on the Kaplan-Meier curve.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Advanced Gastric Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>All Participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All Participants will receive Paclitaxel, Olaparib and Pembrolizumab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Patients will receive treatment on Day 1 and 8.
Paclitaxel (80 mg) will be administered IV on days 1 and 8 (21 day cycle).
Drug - Paclitaxel - 80mg IV</description>
    <arm_group_label>All Participants</arm_group_label>
    <other_name>nab-paclitaxel, Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olaparib</intervention_name>
    <description>Olaparib will be taken by mouth daily for 3 weeks (21 day cycle).
Drug - 100 mg or 300mg</description>
    <arm_group_label>All Participants</arm_group_label>
    <other_name>Lynparza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Patients will receive treatment every 21 days.
Pembrolizumab (200 mg) will be administered IV on day 1 (21 day cycle).
Drug - 200mg IV</description>
    <arm_group_label>All Participants</arm_group_label>
    <other_name>MK-3475; Keytruda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age â‰¥18 years.

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

          -  Must have advanced gastric or gastroesophageal cancer.

          -  Must have received only one line of systemic therapy.

          -  Must have the presence of measurable lesion.

          -  Must agree to have a biopsy.

          -  Life expectancy of greater than 3 months.

          -  Patients must have adequate organ and marrow function defined by study - specified
             laboratory tests.

          -  Woman of childbearing potential must have a negative pregnancy test.

          -  Must use acceptable form of birth control while on study.

          -  Ability to understand and willingness to sign a written informed consent document.

        Exclusion Criteria:

          -  Known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
             Require any antineoplastic therapy.

          -  Require any other form of systemic or localized antineoplastic therapy

          -  Received prior treatment with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4, or with
             an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g.,
             CTLA-4, OX 40, CD137).

          -  Has received prior therapy with taxane or PARP (Poly (ADP-Ribose) Polymerase)
             inhibitor.

          -  Hypersensitivity reaction to any paclitaxel, pembrolizumab or related compounds and/or
             to any of the components.

          -  Allergy to dexamethasone, diphenhydramine and famotidine.

          -  Is taking a moderate or strong CYP3A inhibitor.

          -  Has uncontrolled intercurrent acute or chronic medical illness.

          -  Has a known additional malignancy that is progressing and has required active
             treatment within the past 1 year.

          -  Has received prior systemic anti-cancer therapy including investigational agents
             within 2 weeks prior to study treatment.

          -  Has received prior radiotherapy within 2 weeks of start of study treatment.

          -  Has received a live vaccine within 30 days prior to the first dose of study drug.

          -  Is currently or has participated in another investigational study within 4 weeks prior
             to receiving study drug.

          -  Has an active known or suspected autoimmune disease.

          -  Has a diagnosis of immunodeficiency.

          -  Prior tissue or organ allograft or allogeneic bone marrow transplantation.

          -  Has a history or current evidence of any condition, therapy, or laboratory abnormality
             that might confound the results of the study, interfere with the subject's
             participation for the full duration of the study, or is not in the best interest of
             the subject to participate, in the opinion of the treating investigator. .

          -  Requires daily supplemental oxygen.

          -  History of (non-infectious) pneumonitis that required steroids or has current
             pneumonitis.

          -  History of encephalitis, meningitis, or uncontrolled seizures in the year prior to
             informed consent.

          -  Infection with HIV or hepatitis B or C at screening.

          -  Has uncontrolled infection requiring systemic therapy..

          -  Subjects unable to undergo venipuncture and/or tolerate venous access.

          -  Has known psychiatric or substance abuse disorder that would interfere with
             cooperation with the requirements of the trial.

          -  Woman who are pregnant or breastfeeding.

          -  A woman of childbearing potential (WOCBP) who has a positive urine pregnancy test
             within 72 hours prior to study drug initiation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katherine Bever, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins Medical Institution</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Susan Sartorius-Mergenthaler, RN</last_name>
    <phone>410-614-3644</phone>
    <email>Sartosu@jhmi.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ellen Foreman-Lilly, RN</last_name>
    <phone>443-287-4961</phone>
    <email>lillyel@jhmi.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Sartorius-Mergenthaler, RN</last_name>
      <phone>410-614-3644</phone>
      <email>Sartosu@jhmi.edu</email>
    </contact>
    <contact_backup>
      <last_name>Ellen Foreman-Lilly, RN</last_name>
      <phone>443-287-4961</phone>
      <email>lillyel@jhmi.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>December 20, 2019</study_first_submitted>
  <study_first_submitted_qc>December 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 24, 2019</study_first_posted>
  <last_update_submitted>July 15, 2020</last_update_submitted>
  <last_update_submitted_qc>July 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nab-Paclitaxel</keyword>
  <keyword>Olaparib</keyword>
  <keyword>Pembrolizumab</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Anti-PD-1</keyword>
  <keyword>PARP inhibitors</keyword>
  <keyword>Gastric Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Olaparib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

